We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CLL Cello Health Plc

0.00 (0.00%)
20 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Cello Health Plc LSE:CLL London Ordinary Share GB00B0310763 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 161.00 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 161.00 GBX

Cello Health (CLL) Latest News

Real-Time news about Cello Health Plc (London Stock Exchange): 0 recent articles

Cello Health (CLL) Discussions and Chat

Cello Health Forums and Chat

Date Time Title Posts
18/8/202015:24Cello - solid prospects1,087
29/1/201516:56CELLO GROUP?9
12/1/200516:17Cello or EQI?-

Add a New Thread

Cello Health (CLL) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Cello Health (CLL) Top Chat Posts

Top Posts
Posted at 02/7/2020 16:41 by coopstock
Why would anyone buy at 163p - when agreed price is 161p? Am I missing something?
Posted at 05/6/2020 15:40 by qs99
US market recovery and economic news today, may help CLL....let's see
Posted at 04/6/2020 11:36 by qs99
Having to pay full offer price....DYOR....looking for 10-15% from update key
Posted at 20/5/2020 08:39 by davebowler
Navigating positively through disruptions
Cello’s AGM statement should reassure that FY20 trading to date remains
robust, underpinned by “solid” growth in net revenue in Q1/20. While
Q2/20 saw certain early disruption, overall progress has been made to
maintain revenues alongside effective cost controls, thus a creditable
H1/20E result is expected. The 23% fall in the shares since February’s
highs, appears to overly discount for the actual reality of this disruption.
 Despite some disruption in Q2/20, the Cello Health division continues to perform:
 Q1/20: Cello Health delivered “strong” overall net revenue and profit growth over
Q1/20, benefitting from ISS’s acquisition in August 2019. On a LFL basis, excluding
ISS, organic growth has been described as “good”, continuing recent momentum.
 Q2/20: Commentary on trading post the COVID-19 outbreak suggests of continued
progress, with new win rates being maintained, leading to a continuation of the
typical six month visibility to bookings going into H2/20. This comes despite some
disruption in activities requiring physical proximity (healthcare conventions, expert
focus groups etc), which are being digitally delivered or have been put on hold.
 Some COVID-19 benefits: New projects have arisen as result of the pandemic, with
Cello Connect, the digital and creative marketing capability transferred from Signal,
delivering COVID-19 related public health campaigns, while newly acquired ISS is
also benefitting from new US regulatory drug approvals and FDA fillings.
 Signal expected to be more impacted, but it’s far less material this year: Cello Signal
generated only 16% of net revenue in Q1/20 following Connect’s transfer at the start
of the year. Over Q2/20 and beyond, trading is unsurprisingly expected to be
challenged by COVID-19, given certain clients are engaged in troubled sectors (eg
travel, leisure), thus some delays and cancellations are expected. As such, cost
control measures have, and continue to be undertaken, where necessary.
 Balance sheet remains strong: Today’s update confirms Cello maintains a “solid” net
cash position. This comes despite a seasonal working capital outflow in Q1/20 and is
inclusive of a £0.7m payment for the final earn-out payment on Defined Health and
FY19A’s £1.1m final dividend. The implies positive cash generation to date this year.
 Valuation: Prior to the COVID-19 outbreak, Cello traded at a forward P/E of 16.0x in
late February, a multiple we feel is merited. If Cello were to deliver a FY20E result
largely consistent with FY19A, a price today of 151p p/s (+32% upside) would be fair.
Posted at 07/4/2020 12:37 by coopstock
Cutting the dividend just one week after announcing the award of all those new share options for senior directors. All in this together - I don't think so. Pretty poor.
Posted at 23/3/2020 09:02 by qs99
Any vague return to normality and given HNT purchase recently, IMO this will get bought out if it stays at this price.

Posted at 03/3/2020 12:18 by zipstuck
As the major drug companies are being squeezed on supply chains you have to wonder how this might affect CLL
Posted at 09/1/2020 21:32 by bargainbob
Poikka glad i introduced a little Fanny to the advfn boards and it boosted the share price to heights not seen before.

Good luck reaching 150p
Posted at 08/1/2020 17:33 by f15jcm
I bought for a new position today. With the price at 140p I figured my 17,500 shares would push the price to 12y highs, which seems to have worked.
Posted at 07/1/2020 08:30 by davr0s
Who knows but I buy breakouts like this any day of the week. Shares that are going to go and make big gains have to break out first. No idea where price will end up but gotta be in the game to capture some of these
Cello Health share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock